Co-creating, partnering, and licensing DTx: The trade-offs for pharma on responsibilities, risk, and retaining commercial control
Matt Norton, VP of Marketing & Commercial Development, talks about Co-creating, partnering, and licensing DTx: The trade-offs for pharma on responsibilities, risk, and retaining commercial control:
- What are the trade-offs and potential downsides
- What is the right mix to build success: responsibilities, risk, and commercial control
- Our experience and learnings from the co-creation of DTx
